-0.3 C
Washington

Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug  – Reuters News Agency

Date:

Share:

Health

Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported. This was followed by another exclusive that Catalent’s plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk’s  Wegovy as part of the two companies’ expanded supply agreement. Catalent’s shares briefly jumped on the news. 

Market Impact

Shares in Thermo jumped as much as 4% during New York trading on Wednesday. 

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Source link

Subscribe to our magazine

━ more like this

Cop29: US out, China in – the future of climate talks?

BBCThe WhatsApp message was from the chief negotiator of one of the most powerful countries at the COP climate gathering. Could I stop by...

Teen’s sudden death from peanut allergy leads to dramatic family decision

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - free of...

International Men’s Day 2024? Theme, History, Significance, And Mental Illness In Men – News18

International Men’s Day, observed on November 19, is dedicated to appreciate the contributions of men to society. It highlights their achievements and the challenges...

Data breach exposes over 56 million clothing store customers

Join Fox News for access to this content You have reached your maximum number of articles. Log in or create an account FREE of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here